Boron for Arthritis

Verdict: Weak, industry-tilted signal; not established

Boron shows a tentative, mostly positive signal for arthritis-related joint discomfort, but the evidence is thin, short-term, and heavily industry-funded, so it cannot be considered an established treatment. Major rheumatology bodies and clinics do not recommend it.

C 🟠 C Weak Evidence Published with Warning

🔬Why this grade7-layer evidence engine

The clinical base is genuinely weak (Tier C). It rests on a handful of small, short studies and conceptual papers: an ecological hypothesis comparing arthritis rates in high- versus low-boron regions (PMID 7889887), a tiny n=20 double-blind pilot mixing osteoarthritis and rheumatoid arthritis (PMID 2306060), and calcium-fructoborate work reporting reduced knee discomfort and inflammatory markers (PMID 24940052, PMID 22435474, PMID 21196370). There is no large RCT, systematic review, or meta-analysis.

Direction of effect leans positive, but confidence is limited by quality and conflict of interest. The pivotal calcium-fructoborate trials were largely sponsored by the ingredient's patent holder, triggering a high-industry-funding flag. NIH ODS calls boron a non-essential trace mineral that 'might' help bone and hormone function, while EFSA explicitly concluded a cause-and-effect relationship with joint function has not been established and set a 10 mg/day upper limit.

Mainstream clinical sources do not endorse boron for arthritis. The FDA sets no daily value, and Mayo Clinic, Cleveland Clinic, Harvard Health, the American College of Rheumatology, and the Arthritis Foundation make no mention of it; ACR instead points to omega-3, vitamin D, or turmeric. WHO advises against supplement intakes exceeding its tolerable level. The honest read: a plausible but unproven mineral, not a reliable arthritis remedy.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.40
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published with Warning
Confidence
81%
Highly consistent evidence
Evidence level
E6
Multiple smaller RCTs (n<500)

How strongly each layer supports this effect

lower = less supportive
L2 PubMedPrimary literature
0.40
L1 ExamineGlobal benchmark
0.50
L3 MechanismPlausibility
0.50
L5 Clinical bodiesAuthoritative stance
0.50
L11 AI re-checkIndependent read
0.50
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.402
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 無高階證據可裁決
  4. tier_strict_requirement_check — Tier 條件達標,未降階
  5. detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Essentiality of boron for healthy bones and joints
PMID: 7889887 1994 Observational
Finding: Newnham reported an ecological/observational inverse association: regions with low dietary boron intake (<=1 mg/day, e.g., parts of Jamaica, Mauritius) had OA prevalence 50-70%, whereas high-boron-intake regions (3-10 mg/day, e.g., Israel) had prevalence <10%. Author also describes an open-label observation that 6-9 mg/day boron supplementation produced symptom improvement in some OA patients. Methodologically this is hypothesis-generating only — no randomization, no controls, multiple confounders.
🟠 Limited quality Academic Effect size: Ecological correlation only; no formal effect size
View on PubMed
Calcium fructoborate: plant-based dietary boron for human nutrition (with osteoarthritis open-label data)
PMID: 22435474 2009 RCT (open-label) n = 60
Finding: Short (15-day) Romanian pilot reported reduction in WOMAC, pain and stiffness scores with calcium fructoborate vs placebo at 6 mg/day; open-label/single-blind components, very short duration, small per-arm sample, single research group. Hypothesis-generating; not adequate to establish efficacy.
🟠 Limited quality ⚠️ Industry-funded Effect size: Reductions in WOMAC and pain scores reported as significant within-group; between-group differences modest
View on PubMed
Short-term efficacy of calcium fructoborate on subjects with knee discomfort: a comparative, double-blind, placebo-controlled clinical study
PMID: 24940052 2014 RCT (double-blind) n = 60
Finding: Pietrzkowski et al. double-blind RCT: calcium fructoborate group showed statistically significant within-group and vs-placebo reductions in WOMAC and McGill pain scores at 14 days. Limitations: 2-week duration, n=60, recruited by self-reported knee discomfort rather than radiographic OA, industry-sponsored (Futureceuticals/VDF), single trial.
⚠️ Industry-funded Effect size: WOMAC reduction reported significantly greater vs placebo at 14 days; magnitude small in absolute terms
View on PubMed
Calcium fructoborate: plant-based dietary boron as potential medicine for cancer therapy and inflammatory conditions (review)
PMID: 21196370 2011 Other
Finding: Scorei narrative review collates the same small calcium fructoborate trials (Pietrzkowski 2014, Reyes-Izquierdo / Scorei pilots) and reports consistent direction — modest reductions in hs-CRP and self-reported joint discomfort. Author affiliations include the patent holder; no independent meta-analysis exists. Useful to map the evidence base but does not add new RCT data.
🟠 Limited quality ⚠️ Industry-funded Effect size: No new pooled effect size; qualitative summary only
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Not addressed
Because the FNB has not established an RDA or AI for boron, boron does not have a DV. source↗
L4b EU EFSA
Cautious
The Panel concludes that a cause and effect relationship has not been established between the dietary intake of boron and maintenance of normal bone, normal testosterone concentrations in plasma, or maintenance of joint function. Tolerable Upper Intake Level for boron in adults: 10 mg/day (as boric acid equivalents). source↗
L4d TW TFDA / 衛福部
Cautious
基於硼砂對人體的危害,世界上許多國家包括臺灣都已禁止硼砂在食品保存與防腐中使用。 source↗
L4e WHO
Cautious
Dietary supplements that exceed the TI should be avoided. The TI should be applied with the understanding that boron may provide a physiological benefit for human health. source↗
L5a NIH Office of Dietary Supplements
Cautious
Although boron is not classified as an essential nutrient for humans, it might have beneficial effects on bone formation and maintenance, wound healing, the function of steroid hormones (including vitamin D and estrogen), and brain function. Boron is not known to have any clinically relevant interactions with medications. source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-arthritis-INT-boron-001 繁體中文版 →